From a Colombian Market Observation to a Potential Next-Generation Pharmaceutical Platform
Executive Pitch for Panpharma
Presented by: Juan Pablo Domínguez B.
Concept: Pharmaceutical R&D, formulation innovation and regulated therapeutic development
Potential partner: Panpharma
1. The Opportunity
ZOPLEXXX is a pharmaceutical R&D concept originating from a Colombian observation of the rapidly evolving market for psychoactive substances and emerging ketamine-based therapies.
The proposal is not to commercialize tusi, cocaine, or an illicit drug formulation.
Instead, the central question is:
Can a scientifically defined and clinically validated pharmaceutical formulation be developed from the pharmacological observations associated with complex psychoactive combinations, while eliminating the uncertainty, contamination and uncontrolled dosing associated with illicit products?
This creates a potentially valuable intersection between:
Ketamine research + psychiatric medicine + pharmaceutical formulation + digital healthcare + precision dosing.
2. Why Panpharma?
Panpharma is an appropriate potential partner because the company operates within the pharmaceutical sector and has experience relevant to injectable and hospital medicines.
The strategic proposition is therefore not to ask Panpharma to manufacture an existing illicit formulation.
It is to invite Panpharma to evaluate whether the underlying hypothesis can become a legitimate pharmaceutical discovery program.
The first stage would be a controlled:
ZOPLEXXX Feasibility & Drug Discovery Program
with participation from:
- Pharmaceutical R&D
- Medical Affairs
- Regulatory Affairs
- Clinical Development
- Intellectual Property
- Business Development
3. The Problem
The current landscape has two very different markets.
Regulated pharmaceutical medicine
- Defined active ingredients
- Pharmaceutical-grade manufacturing
- Controlled dosage
- Quality assurance
- Clinical evidence
- Pharmacovigilance
- Regulatory oversight
Illicit psychoactive market
- Variable composition
- Unknown concentrations
- Contamination risk
- Uncontrolled combinations
- No standardized dosing
- Limited medical supervision
The ZOPLEXXX hypothesis begins with this contrast.
The pharmaceutical opportunity is to replace uncertainty with science.
4. The ZOPLEXXX Hypothesis
The initial scientific hypothesis is:
A carefully selected, standardized pharmacological formulation may produce a clinically meaningful therapeutic profile that differs from existing ketamine monotherapy and could potentially address selected psychiatric indications.
This is a research hypothesis, not an established medical claim.
The project would therefore begin by determining:
- Which pharmacological mechanisms are relevant?
- Which compounds, if any, merit investigation?
- What combinations are scientifically defensible?
- What safety concerns exist?
- What therapeutic indication has the strongest rationale?
- Is there patentable intellectual property?
- Is the potential market large enough to justify development?
5. The “Tusi” Observation
The Colombian phenomenon commonly referred to as “tusi” or “pink cocaine” is particularly interesting from a public-health and pharmaceutical research perspective because it is not a standardized pharmaceutical product.
Different samples can contain different substances and concentrations.
That variability creates significant health risks.
For ZOPLEXXX, the phenomenon should therefore be treated as:
A market and sociological observation — not a pharmaceutical formulation.
The scientific proposition is to investigate whether any clinically useful pharmacological principles can be identified and developed independently through legitimate pharmaceutical research.
6. The Transformation
The conceptual transformation is:
Illicit market
Variable composition
↓
Unknown dose
↓
Unknown interactions
↓
Uncontrolled manufacturing
↓
Health risks
ZOPLEXXX pharmaceutical pathway
Scientific hypothesis
↓
Defined formulation
↓
Pharmaceutical-grade ingredients
↓
Preclinical testing
↓
Clinical trials
↓
Regulatory approval
↓
Pharmacovigilance
↓
Potential global product
7. Ketamine as the Starting Point
Ketamine has generated significant scientific interest in psychiatry, particularly regarding rapid-acting antidepressant mechanisms.
Esketamine has an FDA-approved indication for specific patients with treatment-resistant depression, under a controlled regulatory framework.
This demonstrates that the broader scientific question surrounding glutamatergic mechanisms and rapid-acting psychiatric therapies is already commercially and clinically relevant.
ZOPLEXXX would seek to determine whether there is an additional therapeutic opportunity beyond existing products.
8. Important Scientific Boundary
ZOPLEXXX should not initially be defined as:
Ketamine + clonazepam + Prozac.
That would be premature and scientifically weak.
The correct question is:
Which pharmacological combination, if any, demonstrates an acceptable balance of efficacy, safety, tolerability and clinical utility?
Benzodiazepines also require particular scrutiny because of potential sedation and respiratory-depression risks when combined with ketamine, and because benzodiazepine exposure may affect ketamine’s therapeutic response.
Therefore, any combination would need to be determined through formal pharmacological and clinical research.
9. Potential Therapeutic Areas
Subject to scientific validation, potential areas of investigation could include:
- Treatment-resistant depression
- Major depressive disorder
- Trauma-related psychiatric disorders
- Anxiety disorders
- Substance-use disorders
- Other neuropsychiatric conditions
These are research indications, not claims that ZOPLEXXX treats these conditions.
Each indication would require its own clinical evidence.
10. Business Model
ZOPLEXXX could eventually create value through four interconnected assets:
1. Pharmaceutical Product
A proprietary, regulated therapeutic product.
2. Intellectual Property
Potential patents covering:
- formulation;
- composition;
- manufacturing;
- therapeutic use;
- delivery technology.
3. Clinical Platform
Potential integration with:
- telemedicine;
- patient monitoring;
- digital assessments;
- treatment adherence;
- clinical follow-up.
4. Research Platform
Long-term development of additional compounds and therapeutic applications.
11. SWOT / DOFA Analysis
|
Strengths |
Opportunities |
|
Panpharma pharmaceutical capabilities |
Growth of psychedelic and ketamine research |
|
Existing pharmaceutical infrastructure |
Rapid-acting psychiatric therapies |
|
Potential access to R&D expertise |
Digital mental-health platforms |
|
Distinctive Colombian origin story |
Global pharmaceutical markets |
|
Potential IP opportunity |
University and biotech partnerships |
|
Strong differentiation |
New therapeutic indications |
|
Weaknesses |
Threats |
|
No clinical evidence yet |
Strict regulatory requirements |
|
Candidate formulation not established |
Clinical-development costs |
|
Significant R&D investment required |
Existing pharmaceutical competitors |
|
Association with the “tusi” name |
Reputation and compliance risk |
|
Patent landscape unknown |
Safety and abuse-potential concerns |
|
Therapeutic indication uncertain |
Regulatory changes |
12. Development Roadmap
Stage 0 — Feasibility
3–6 months
- Scientific literature review
- Patent landscape
- Regulatory assessment
- Market analysis
- Pharmacological hypothesis
- Preliminary formulation strategy
Decision:
GO / NO-GO
Stage 1 — Drug Discovery
6–18 months
- Candidate identification
- Formulation research
- Analytical development
- Pharmacokinetics
- Preliminary safety assessment
- Drug-interaction research
Deliverable:
Lead candidate
Stage 2 — Preclinical Development
Evaluation of:
- toxicology;
- pharmacokinetics;
- metabolism;
- safety;
- abuse potential;
- drug interactions.
Deliverable:
Preclinical development package
Stage 3 — Clinical Development
Phase I
Safety and tolerability
Phase II
Preliminary efficacy and dose optimization
Phase III
Confirmatory clinical evidence
Phase IV
Post-market safety and pharmacovigilance
All stages would remain subject to the applicable regulatory requirements.
13. Strategic Positioning
The key message should be:
ZOPLEXXX is not an attempt to legalize an illicit drug.
It is a proposal to investigate whether a phenomenon originating in an illicit market can generate a legitimate pharmaceutical research hypothesis.
That distinction is critical.
The value proposition is:
Observation → Science → Drug Discovery → Evidence → Intellectual Property → Regulation → Global Market
14. Why Now?
Three trends are converging:
1. Psychiatric treatment innovation
Growing scientific interest in rapid-acting mechanisms.
2. Digital healthcare
Patients increasingly access healthcare through digitally enabled clinical models.
3. Pharmaceutical personalization
The industry is moving toward more precise treatment strategies based on patient characteristics, clinical response and controlled dosing.
ZOPLEXXX sits at the intersection of these trends.
15. Potential Strategic Structure
PANPHARMA
Pharmaceutical development
↓
ZOPLEXXX R&D PROGRAM
Drug discovery + formulation
↓
UNIVERSITIES / RESEARCH CENTERS
Neuroscience + pharmacology
↓
CLINICAL PARTNERS
Clinical development
↓
DIGITAL HEALTH PARTNER
Patient monitoring + clinical support
↓
GLOBAL MARKETS
Regulated pharmaceutical commercialization
16. The Colombian Innovation Angle
The Colombian origin of ZOPLEXXX should be positioned carefully.
The story should not be:
“Colombia invented tusi.”
The stronger story is:
“A Colombian observation of a complex social and pharmacological phenomenon generated a pharmaceutical research hypothesis.”
Colombia can potentially contribute:
- scientific talent;
- pharmaceutical research;
- biodiversity research;
- clinical research infrastructure;
- entrepreneurial talent;
- Latin American market access.
The objective is to transform a difficult historical legacy into legitimate innovation.
17. Investment Thesis
The investment thesis is simple:
Existing phenomenon
There is a large global demand for psychoactive substances and psychiatric treatments.
Existing scientific platform
Ketamine and related mechanisms are already the subject of significant medical research.
Existing problem
Illicit psychoactive products have uncontrolled composition and dosing.
Proposed opportunity
Develop a completely standardized, evidence-based pharmaceutical candidate.
Potential value
A successful product could create:
Revenue + IP + licensing opportunities + clinical data + international partnerships.
18. What I Am Asking Panpharma to Do
I am not asking Panpharma to approve ZOPLEXXX as a medicine.
I am asking Panpharma to evaluate whether the concept deserves scientific investigation.
The first step could be a confidential feasibility review covering:
Scientific feasibility
Can the hypothesis be scientifically tested?
Regulatory feasibility
What regulatory pathway would apply?
Intellectual property
Is there a patentable opportunity?
Clinical feasibility
Which indication should be investigated?
Commercial feasibility
Could the eventual product justify the development cost?
19. Proposed First Meeting
60–90 Minute Strategic Workshop
Participants
- Panpharma R&D
- Medical Affairs
- Regulatory Affairs
- Business Development
- Intellectual Property
- ZOPLEXXX project representative
Agenda
20 min — Market observation
20 min — Scientific hypothesis
15 min — Pharmaceutical opportunity
15 min — Regulatory/IP considerations
15 min — Development roadmap
5 min — Next steps
20. The Executive Message
ZOPLEXXX
From a Colombian observation to a global pharmaceutical opportunity.
The illicit psychoactive market demonstrates something that pharmaceutical science should not ignore: people are seeking specific alterations in mood, perception, anxiety, productivity and psychological states.
The illicit market responds to that demand with uncontrolled mixtures, unknown concentrations and significant health risks.
Pharmaceutical science can approach the same underlying problem differently.
Define the molecules.
Control the formulation.
Study the mechanisms.
Test safety.
Demonstrate efficacy.
Protect the intellectual property.
Regulate the product.
And only then build the market.
ZOPLEXXX is therefore not a proposal to commercialize tusi.
It is a proposal to determine whether the observations surrounding that phenomenon can lead to a new pharmaceutical research program.
If the science does not work, we stop.
If the science works, Panpharma could potentially have a new pharmaceutical asset.
21. Closing Pitch to Panpharma
Dear Panpharma Team,
I believe there is an opportunity worth investigating.
My proposal comes from a Colombian observation of the rapidly evolving psychoactive market and the emergence of ketamine-based therapeutic models.
I am not proposing the commercialization of an illicit substance.
I am proposing a scientific question:
Can we identify and develop a safe, standardized and clinically useful pharmaceutical formulation inspired by the pharmacological phenomena observed in complex psychoactive mixtures?
Panpharma has the pharmaceutical capabilities to determine whether this hypothesis has scientific and commercial merit.
The first step does not require a large investment.
It requires a feasibility assessment.
If the answer is no, we move on.
If the answer is yes, we build the science, protect the intellectual property and develop the regulatory pathway.
ZOPLEXXX
A Colombian observation.
A pharmaceutical hypothesis.
A potential global asset.
Science first. Regulation first. Patients first.